Cargando…

Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy

PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy...

Descripción completa

Detalles Bibliográficos
Autores principales: Takatsuka, Daiki, Yoshimura, Akiyo, Sawaki, Masataka, Hattori, Masaya, Kotani, Haruru, Kataoka, Ayumi, Horisawa, Nanae, Ozaki, Yuri, Endo, Yuka, Nozawa, Kazuki, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139842/
https://www.ncbi.nlm.nih.gov/pubmed/37051648
http://dx.doi.org/10.4048/jbc.2023.26.e13
_version_ 1785033035204263936
author Takatsuka, Daiki
Yoshimura, Akiyo
Sawaki, Masataka
Hattori, Masaya
Kotani, Haruru
Kataoka, Ayumi
Horisawa, Nanae
Ozaki, Yuri
Endo, Yuka
Nozawa, Kazuki
Iwata, Hiroji
author_facet Takatsuka, Daiki
Yoshimura, Akiyo
Sawaki, Masataka
Hattori, Masaya
Kotani, Haruru
Kataoka, Ayumi
Horisawa, Nanae
Ozaki, Yuri
Endo, Yuka
Nozawa, Kazuki
Iwata, Hiroji
author_sort Takatsuka, Daiki
collection PubMed
description PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy (SLNB) should be performed for neoadjuvant chemotherapy (NAC) patients with negative FNAC results is uncertain. This study aimed to determine the role of FNAC before NAC in the evaluation and management of AxLN in early breast cancer patients. METHODS: We retrospectively analyzed 3,810 clinically node-negative (a lymph node with no clinical metastasis without FNAC or radiological suspicion of metastasis with negative FNAC results) patients with breast cancer who underwent SLNB between 2008 and 2019. We compared the positivity rate of sentinel lymph nodes (SLNs) between patients who received and those who did not receive NAC with negative FNAC results or without FNAC and axillary recurrence rate in the neoadjuvant group with negative SLNB results. RESULTS: In the non-neoadjuvant (primary surgery) group, the positivity rate of SLNs in patients with negative FNAC results was higher than that in patients without FNAC (33.2% vs. 12.9%; p < 0.001). However, the SLN positivity rate of patients with negative FNAC results (false-negative rate for FNAC) in the neoadjuvant group was lower than that in the primary surgery group (3.0% vs. 33.2%; p < 0.001). After a median follow-up of 3 years, one axillary nodal recurrence was observed, which was a case from the neoadjuvant non-FNAC group. None of the patients in the neoadjuvant group with negative FNAC results had axillary recurrence. CONCLUSION: The false-negative rate for FNAC in the primary surgery group was high; however, SLNB was the proper axillary staging procedure for NAC patients who have clinically suspicious AxLN metastases on radiologic examination but negative FNAC results.
format Online
Article
Text
id pubmed-10139842
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Breast Cancer Society
record_format MEDLINE/PubMed
spelling pubmed-101398422023-04-29 Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy Takatsuka, Daiki Yoshimura, Akiyo Sawaki, Masataka Hattori, Masaya Kotani, Haruru Kataoka, Ayumi Horisawa, Nanae Ozaki, Yuri Endo, Yuka Nozawa, Kazuki Iwata, Hiroji J Breast Cancer Original Article PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy (SLNB) should be performed for neoadjuvant chemotherapy (NAC) patients with negative FNAC results is uncertain. This study aimed to determine the role of FNAC before NAC in the evaluation and management of AxLN in early breast cancer patients. METHODS: We retrospectively analyzed 3,810 clinically node-negative (a lymph node with no clinical metastasis without FNAC or radiological suspicion of metastasis with negative FNAC results) patients with breast cancer who underwent SLNB between 2008 and 2019. We compared the positivity rate of sentinel lymph nodes (SLNs) between patients who received and those who did not receive NAC with negative FNAC results or without FNAC and axillary recurrence rate in the neoadjuvant group with negative SLNB results. RESULTS: In the non-neoadjuvant (primary surgery) group, the positivity rate of SLNs in patients with negative FNAC results was higher than that in patients without FNAC (33.2% vs. 12.9%; p < 0.001). However, the SLN positivity rate of patients with negative FNAC results (false-negative rate for FNAC) in the neoadjuvant group was lower than that in the primary surgery group (3.0% vs. 33.2%; p < 0.001). After a median follow-up of 3 years, one axillary nodal recurrence was observed, which was a case from the neoadjuvant non-FNAC group. None of the patients in the neoadjuvant group with negative FNAC results had axillary recurrence. CONCLUSION: The false-negative rate for FNAC in the primary surgery group was high; however, SLNB was the proper axillary staging procedure for NAC patients who have clinically suspicious AxLN metastases on radiologic examination but negative FNAC results. Korean Breast Cancer Society 2023-03-17 /pmc/articles/PMC10139842/ /pubmed/37051648 http://dx.doi.org/10.4048/jbc.2023.26.e13 Text en © 2023 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Takatsuka, Daiki
Yoshimura, Akiyo
Sawaki, Masataka
Hattori, Masaya
Kotani, Haruru
Kataoka, Ayumi
Horisawa, Nanae
Ozaki, Yuri
Endo, Yuka
Nozawa, Kazuki
Iwata, Hiroji
Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title_full Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title_fullStr Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title_full_unstemmed Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title_short Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
title_sort evaluation of the role of axillary lymph node fine-needle aspiration cytology in early breast cancer with or without neoadjuvant chemotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139842/
https://www.ncbi.nlm.nih.gov/pubmed/37051648
http://dx.doi.org/10.4048/jbc.2023.26.e13
work_keys_str_mv AT takatsukadaiki evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT yoshimuraakiyo evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT sawakimasataka evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT hattorimasaya evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT kotaniharuru evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT kataokaayumi evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT horisawananae evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT ozakiyuri evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT endoyuka evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT nozawakazuki evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy
AT iwatahiroji evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy